Janney Montgomery Scott Downgrades Assertio Therapeutics (ASRT) to Neutral
- Bonds take a breather, Tencent tumbles
- 'Becoming JP Morgan of the Future': Square (SQ) Dips on Deal to Acquire BNPL Afterpay For $29B in Stock, Benefits Outweigh High Price Says Analyst
- Oil falls over 3% on concerns over demand and OPEC supply boost
- ON Semiconductor (ON) Surges on Strong Q2 Results and Q3 Outlook
- Dollar wavers on dovish Fed tone, mixed economic outlook
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Janney Montgomery Scott analyst Ken Trbovich downgraded Assertio Therapeutics (NASDAQ: ASRT) from Buy to Neutral.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: JPMorgan Downgrades Magenta Therapeutics (MGTA) to Neutral
- Barclays Downgrades TUI AG (TUI1:GR) (TUIFY) to Underweight
- UPDATE: JPMorgan Downgrades US Cellular (USM) to Underweight
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesJanney Montgomery Scott
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!